Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 566,451
  • Shares Outstanding, K 70,895
  • Annual Sales, $ 430 K
  • Annual Income, $ -88,450 K
  • 60-Month Beta 0.05
  • Price/Sales 1,329.70
  • Price/Cash Flow N/A
  • Price/Book 2.91
Trade ALT with:

Options Overview Details

View History
  • Implied Volatility 118.04% ( -4.24%)
  • Historical Volatility 90.77%
  • IV Percentile 48%
  • IV Rank 17.64%
  • IV High 356.79% on 10/24/23
  • IV Low 66.90% on 08/23/23
  • Put/Call Vol Ratio 0.20
  • Today's Volume 8,074
  • Volume Avg (30-Day) 9,231
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 103,007
  • Open Int (30-Day) 100,970

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.36
  • Number of Estimates 4
  • High Estimate -0.30
  • Low Estimate -0.43
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.32 +3.14%
on 04/15/24
11.01 -31.43%
on 04/01/24
-2.31 (-23.43%)
since 03/15/24
3-Month
7.32 +3.14%
on 04/15/24
14.84 -49.12%
on 02/28/24
-4.45 (-37.08%)
since 01/12/24
52-Week
2.09 +261.24%
on 10/23/23
14.84 -49.12%
on 02/28/24
+2.77 (+57.95%)
since 04/14/23

Most Recent Stories

More News
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.

Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.

VKTX : 66.95 (-2.43%)
LLY : 750.77 (-0.12%)
PFE : 25.91 (+0.19%)
ALT : 7.55 (-5.51%)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?

Viking Therapeutics just might be an attractive acquisition target for Pfizer.

LLY : 750.77 (-0.12%)
NVO : 123.90 (-0.49%)
ALT : 7.55 (-5.51%)
PFE : 25.91 (+0.19%)
VKTX : 66.95 (-2.43%)
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?

Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.

UBS : 28.42 (-1.08%)
VKTX : 66.95 (-2.43%)
NVO : 123.90 (-0.49%)
LLY : 750.77 (-0.12%)
ALT : 7.55 (-5.51%)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

VKTX : 66.95 (-2.43%)
AMGN : 265.51 (-0.66%)
LLY : 750.77 (-0.12%)
ENDP : 0.2926 (-5.00%)
PFE : 25.91 (+0.19%)
ALT : 7.55 (-5.51%)
Is Viking Therapeutics a Smart Buy on the Dip?

The stock recently fell around 25% for reasons that had nothing to do with its lead program.

NVO : 123.90 (-0.49%)
VKTX : 66.95 (-2.43%)
ALT : 7.55 (-5.51%)
MDGL : 231.37 (-2.21%)
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

BIIB : 196.80 (-0.70%)
GILD : 67.75 (-0.47%)
INCY : 53.43 (-0.78%)
ALT : 7.55 (-5.51%)
KRTX : 329.83 (+0.03%)
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data

Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....

ALT : 7.55 (-5.51%)
RCEL : 9.46 (-4.25%)
AVTX : 15.24 (+2.28%)
EQRX : 2.34 (-2.09%)
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.

It's not the end of the story for this once high-flying biotech stock.

ALT : 7.55 (-5.51%)
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week

Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.

ALT : 7.55 (-5.51%)
FHTX : 6.39 (-13.88%)
PGEN : 1.4000 (-1.41%)
Zoetis' (ZTS) Q4 Earnings in Line With Estimates, Revenues Beat

Zoetis' (ZTS) fourth-quarter 2022 earnings per share was at par with the Zacks Consensus Estimate, while revenues beat the same. The company provides its financial guidance for 2023.

ALT : 7.55 (-5.51%)
ZTS : 149.77 (-0.14%)
ALVR : 0.7461 (-2.71%)
EQRX : 2.34 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 8.57
2nd Resistance Point 8.28
1st Resistance Point 7.91
Last Price 7.55
1st Support Level 7.25
2nd Support Level 6.96
3rd Support Level 6.59

See More

52-Week High 14.84
Fibonacci 61.8% 9.97
Fibonacci 50% 8.47
Last Price 7.55
Fibonacci 38.2% 6.96
52-Week Low 2.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar